Annual report pursuant to Section 13 and 15(d)

Acquisitions, Investments, and Licenses - Summary of Assets Acquired and Liabilities Assumed (Details)

v2.4.0.8
Acquisitions, Investments, and Licenses - Summary of Assets Acquired and Liabilities Assumed (Details) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Mar. 31, 2013
Cytochroma acquisition [Member]
Mar. 31, 2013
Cytochroma acquisition [Member]
Patents [Member]
Mar. 31, 2013
Cytochroma acquisition [Member]
In Process Research and Development [Member]
Dec. 31, 2013
PROLOR [Member]
Aug. 29, 2013
PROLOR [Member]
Aug. 29, 2013
PROLOR [Member]
Patents [Member]
Aug. 29, 2013
PROLOR [Member]
In Process Research and Development [Member]
Business Acquisition [Line Items]                    
Current assets       $ 1,224 [1]       $ 21,500 [1]    
Intangible assets:                    
In-process research and development           191,530       590,200
Patents         210       0  
Total intangible assets       191,740       590,200    
Goodwill 226,373 [2] 80,450 [2] 39,815 2,411     139,784 139,784    
Property, plant and equipment       306       1,057    
Other assets       0       371    
Accounts payable and accrued expenses       (1,069)       (9,866)    
Business Acquisition, Purchase Price Allocation, Deferred Taxes Asset (Liability), Net, Noncurrent       0       (156,403)    
Total purchase price       194,612       586,643    
Current assets include cash       $ 400       $ 20,500    
[1] Current assets include cash of $0.4 million and $20.5 million related to the Cytochroma and PROLOR acquisitions, respectively
[2] As of December 31, 2013 and 2012, total assets include $6.7 million and $5.6 million, respectively, and total liabilities include $10.4 million and $5.5 million, respectively related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and the holders of SciVac’s consolidated liabilities have no recourse against us. Refer to Note 3.